Recent evidence suggests that the potent constrictor peptide, endothelin (ET) has a mediating role in cyclosporine A (CsA)-related renal vasoconstriction. However, the nature of the CsA-ET interaction and effect on the renal vasculature is uncertain. The purpose of the present study was twofold: (a) to determine if CsA exposure caused direct local release of ET from the endothelium of the renal microvasculature and (b) to determine if locally generated ET has paracrine effects on the underlying vascular smooth muscle to induce vasoconstriction. Experiments were performed in isolated rat renal arterioles. First it was determined that both afferent arteriole (AA) and efferent arteriole (EA) exhibited concentration-dependent decreases in lumen diameter to increasing molar concentrations of CsA. The AA was more sensitive to the vasoconstrictive effects of CsA than the EA. Next, the blocking effect of a recently synthesized putative ETA receptor antagonist was verified in both the AA and EA, where it was found that the cyclic peptide cyclo D-Asp-L-Pro-D-Val-L-Leu-D-Trp totally inhibited the vasoconstriction observed with ET addition. Finally, the role of locally stimulated ET in CsA-induced vasoconstriction was tested by determining the effect of the ETA receptor antagonist on CsA-induced AA and EA constriction. In the AA the vasoconstrictor effect of 1011 M CsA was completely blocked by the ETA receptor antagonist. However, in contrast to AA, 10 1 M CsA in EA in the presence of the ETA receptor antagonist decreased EA lumen diameter by a mean of 41% from baseline (4.80±0.75 ,um vs 7.80±0.84 ,tm, P < 0.05). This change in lumen diameter was similar to that induced by CsA alone. These data suggest that CsA directly constricts renal microvessels. This effect is mediated by ET in the AA but not the EA. (J.
Introduction
Cyclosporine A (CsA)' is an effective immunosuppressive agent; however, its clinical efficacy is complicated by substantial nephrotoxicity. The exact mechanism for CsA-induced nephrotoxicity is unclear, but a growing body of evidence sug-gests that the primary pathogenetic mechanism may be vascular (1) (2) (3) . The vascular effects of CsA in animal models have included sustained vasoconstriction in both the pre-and postglomerular circulation (4) (5) (6) (7) (8) (9) . While a direct effect has not been absolutely excluded, a number of physiologic agonists have been implicated as mediators of CsA-induced vasoconstriction. Recent evidence has supported a potentially important role for the potent constrictor peptide, endothelin (ET), in the effects of CsA on vascular smooth muscle (6) . The exact role played by ET in CsA-induced vasoconstriction is uncertain. A number of investigators have demonstrated an increase in urinary ET excretion in rats after acute CsA infusion (10, 11) . The study of Bunchman et al. ( 12) showing concentration-dependent CsA induction of ET synthesis in cultured endothelial cells would indicate that CsA may directly stimulate increased ET activity in the systemic or renal vasculature. On the other hand, the findings of Zimmerhackl et al. ( 13) suggest that ET stimulation by CsA may be more complex. Using the hydronephrotic rat kidney, they showed that CsA-induced vasoconstriction was limited to the more proximal vessels, i.e., arcuate and interlobular arteries. Thus, it is possible that the proximal vasoconstrictor effect of CsA is either direct, or mediated by another agonist, and the increase in ET activity is secondary to distal arterial ischemia, a potent stimulus of ET release ( 14) .
In addition to the question regarding the mechanism of stimulation, there is also uncertainty surrounding the mode and site of action of ET released by CsA exposure. Kon et al. (6) reported an attenuation of acute CsA-induced renal vasoconstriction and glomerular dysfunction with renal arterial infusion of rabbit anti-porcine endothelin antibody. Presumably, the molecular radius of such an antibody was too large to permit significant extravascular movement into the subintimal or perivascular space suggesting its primary effect likely involved the binding of circulating ET. On the other hand, there is evidence that ET released from endothelial cells acts primarily by a paracrine mechanism, binding to receptors on adjacent smooth muscle cells ( 15, 16) . Theoretically, such a mechanism would not be affected by an anti-ET antibody with limited access to the subintimal space. Thus the extent to which CsAinduced ET acts by an immediate paracrine mechanism or by release into the circulation with subsequent binding to downstream smooth muscle cell receptors after gaining access to the perivascular and subendothelial spaces is unresolved.
The purpose of the present study was, first, to determine whether CsA exposure caused direct local release of ET from the endothelium ofthe renal microvasculature in either pre-or postglomerular resistance vessels and, second, to determine if locally generated ET could act in a paracrine fashion on the underlying vascular smooth muscle to induce vasoconstriction. The isolated renal arteriolar vessel technique was used to address these questions. As the initial step, CsA concentration related changes in afferent (AA) and efferent arteriolar (EA) lumen diameters were measured. Next, the effect of a new cy-clic pentapeptide ETA receptor antagonist on ET-1-induced AA and EA vasoconstriction was determined ( 17) . Finally, the effect of the ETA receptor antagonist on CsA-induced AA and EA constriction was assessed.
Methods
The in vitro-isolated rat arteriole technique used in these experiments has been described in detail previously ( 18, 19) . Sprague-Dawley rats (200-250 g) that had been given standard rat chow and water ad lib. for 1 wk were anesthetized with methoxyflurane. The kidneys were removed through a midline abdominal incision and immediately place in a 4VC dissecting media of Krebs-Ringer bicarbonate buffer (pH 7.4) consisting of (mM) NaCl 115, NaHCO3 25, K2PO4 2. ( 19) . The intraluminal pressure ofthe vessel was then set at a predetermined value with a syringe connected through a pressure transducer (100Db; Statham Instruments, Oxnard, CA) and a series of stopcocks to the luminal perfusion pipette. Pressure was recorded on a recorder (Statham). The intraluminal pressure was set at 80 mmHg for AA and 30 mmHg for EA. When placed in the perfusion chamber under high power magnification (Xl, 100) AA and EA were readily distinguished by their appearance, which had been determined previously from isolated glomeruli found to have both arterioles attached. The identifying criteria were detailed in earlier publications ( 18, 19) . The vessel was then perfused at 370C for 30 min before experimental manipulations with a perfusate identical to the previously described dissecting medium. The bathing solution (referred to in this study as "standard" bathing medium) was also identical to the dissecting medium except that it did not contain albumin. Albumin in the bathing solution was found to promote bacterial growth, which caused deterioration of the vessels. All bathing solutions were gassed with 80% 02/20% CO2 for 30 min before use. The bathing solution was continuously pumped through the chamber at 1.0 ml/min. During experiments water-saturated gas (80% 02/20% C02) was gently blown over the surface ofthe chamber to maintain pH at 7.40 which was measured frequently with a microliter pH meter (Radiometer, Copenhagen, Denmark).
The arterioles were observed at the above magnification with the use of a microscope, an attached camera and video monitor. Lumen diameter was measured directly from the monitor screen at various points along the vessel. Repeated measurements were made at these same points. Means ofthe measurements were calculated. Experiments were recorded on videotape. The viability ofthe vessels was assessed by the appearance of the intact wall and response to known vasoconstrictor agonists of established potency for this technique such as angiotensin II (All) and NE.
The following protocols were carried out: (a) Effects of CsA and CsA vehicle on AA and EA. Control measurements of AA and EA lumen diameters were made at 1-min intervals for 2 min. The standard bath was quickly changed to a standard bath containing either a known molar concentration of CsA or an equivalent concentration of CsA vehicle (Cremophor®). Because of both the prolonged vasoconstrictor effect and potential toxicity of repeated and cumulative CsA exposure, each vessel was exposed to only a single molar concentration of CsA. Lumen diameter was measured after 2 and 4 min of incubation.
(b) Effects ofET antagonist on ET-induced vasoconstriction ofAA and EA. Concentration response curves to increasing molar concentrations of ET were previously determined by our laboratory ( 16) . Using known near maximal concentrations of ET for AA ( 10 -1 M) and EA ( 10-11 M), changes in lumen diameter with ET alone were compared to changes observed with ET in the presence ofthe putative ETA receptor antagonist (Cyclo D-Asp-L-Pro-D-Val-L-Leu-D-Trp; Peptides International Inc., Louisville, KY). The vasoconstrictor inhibiting effect of the ETA receptor antagonist was tested by adding an excess concentration of the antagonist to the bathing medium ( l0-7 M in the AA and 10-6 M in the EA) after baseline lumen diameters were measured. Since the ETA receptor antagonist had some agonist effect, a maximal concentration ofthe antagonist that caused a < 10% change in baseline lumen diameter was chosen. Lumen diameter was again measured 4 min after adding the antagonist. ET was then added in AA and EA at the same respective concentrations as cited above in the presence ofthe antagonist. Lumen diameter was again measured after 2 and 4 min of incubation. The bath was then exchanged several times with the standard bathing medium. As a postcontrol step to assure vessel viability and reactivity, near EC50 All ( 10-'0 M in AA, 10-11 in EA) was added to the bathing media and changes in vessel lumen diameters were measured. Like ET, the ETA receptor antagonist appeared to have a prolonged affinity for the receptor and, as a consequence, ET could not be used as a postcontrol vasoconstrictor.
(c) Effects ofETantagonist on CsA-induced vasoconstriction in AA and EA. AA and EA were bathed in standard media and baseline lumen diameters measured. The ET antagonist was added to the bathing medium at the respective concentrations for AA and EA given above. The vessels were allowed to incubate for 4 min and repeat lumen diameters measured. CsA ( 10-" M in AA and 10-" M in EA) was added to the bathing medium in the presence of the ET antagonist and lumen diameters measured at 2 and 4 min. If the vessel failed to constrict in response to the above experimental manipulation, then the bath was exchanged several times. After lumen diameter was determined to be stable by repeated measurements, All was added to the bath and changes in vessel lumen diameter recorded to affirm vessel viability and reactivity.
Data analysis and calculations. Data are expressed as mean±SEM. Except for the CsA concentration-response curves, the data are presented as actual lumen diameters in micrometers. CsA concentrationresponse data were presented as percent constriction to establish EC50 and maximal constricting concentrations. Values for mean dose ofthe agent required to produce 50% of maximal contraction was defined as the EC50. Two methods can be used to calculate the EC50. The first method, recently reviewed by Meddings et al. (20) , determines the EC50 from best-fit curve nonlinear regression analysis. The second method uses the means of the individual vessel dose response curve at 50% contraction. Both methods yielded numbers that were not different from the other. In this study the second method was used. Maximal constriction was considered to be that concentration at which there was no further decrease in lumen diameter with addition ofthe next higher log concentration. Maximal constriction in every vessel occurred at < 2 ,um absolute mean lumen diameter. Comparisons of sequential responses within a group were made by repeated measures ANOVA and Scheffe's method for individual comparisons (21 ) . An unpaired t test was used to compare changes in lumen diameter to similar experimental maneuvers in separate study groups and between AA and EA with the same experimental maneuvers. P < 0.05 was considered statistically significant. EA (n = 24) was less sensitive than the AA to CsA with an EC50 value of 3.1±0.7 X 10-11 M (P < 0.05). The CsA vehicle, applied in the diluent concentrations used with CsA in this study, had no effect on vessel lumen diameter in either the AA (n = 4) or EA (n = 4). Reactivity of these latter vessels was verified, however, by documenting their response to EC50 All.
Results

Effects
Effects of the ET antagonist on ET-induced vasoconstriction ofAA and EA. The data for AA and EA, respectively, are _1 /shown in Figs. 3 There was a concentration-dependent decrease in lumen diameter with increasing molar concentrations of CsA. The EA was less sensitive than the AA to the vasoconstrictive effects of CsA (P < 0.05).
The calculated EC50 value was 3.1±0.7 x 10" M. by CsA, on the other hand, did not require ET-ETA interaction. The results of this study, in part, confirm the in vivo findings of Kon et al. (6) which showed that infusion of an ET antibody attenuated the renal vasopressor effects of CsA. In addition, an in vitro study by Takeda et al. ( 17) demonstrated that the ETA receptor antagonist blocked CsA-induced myosin light chain phosphorylation, a biochemical assessment of mesangial cell contraction in culture. However, the model and design of the current study permitted examination of additional specific questions regarding cyclosporine A's vascular effects and the nature of the mediating role of ET. These questions included the site ofvascular action ofCsA, the potential importance of ischemia in CsA-induced ET release, the possibility of a direct paracrine effect ofCsA-stimulated ET on adjacent vascular smooth muscle cells and the importance ofET mediation in pre-and postglomerular arterial vessels.
While the data of this study do not address the constrictor response of more proximal renal arterial vessels to CsA, they clearly show that the immediate juxtaglomerular vasculature is directly responsive to CsA at concentrations that are at least an order of magnitude lower than the generally accepted plasma therapeutic range in renal transplant patients (22) . These results differ' from those of Zimmerhackl ( 13) who showed arcuate and interlobular artery, but not arteriolar, constriction with CsA infusion in the hydronephrotic rat kidney. It is possible that there was a reactive autoregulatory vasodilatation of the more distal vasculature associated with constriction of arcuate and interlobular arteries in the intact kidney that obscured a direct or mediated constrictor effect of CsA. The presconfirmed with All ( 10-11 M) which decreased mean lumen diameter to 1.41±0.92 ,um (P < 0.05).
Effects of the ET antagonist on CsA-induced vasoconstriction in the AA and EA. Data are presented in Figs. 5 (Fig. 2) .
Discussion
The present study demonstrated that in isolated resistance arterial vessels, devoid of systemic and renal parenchymal neurohumoral influences, CsA caused a concentration-dependent constrictor effect. Cyclosporine A vasoconstriction in the AA required the mediation of ETA receptor activation by assumed CsA-stimulated synthesis and release ofET. Constriction ofEA Kon et al. (6) suggested that the ET-mediating role of CsA vasoconstriction might have been different in AA and EA. The reduction in afferent arteriolar resistance with ET antibody infusion was, in fact, twofold greater than the observed decline in efferent arteriolar resistance suggesting that antagonism of ET had a greater impact on CsA-induced tone in AA. Other physiologic agonists have been implicated in the renal vasoconstrictor effects ofCsA including All, catecholamines, platelet-activating factor, and thromboxane A2 (7, (24) (25) (26) (27) (28) (29) . Additional experiments will be required to determine mediated and direct effects ofCsA in the postglomerular vasculature.
